瑞舒伐他汀对急性冠状动脉综合征患者C反应蛋白及血脂的影响

目的探讨瑞舒伐他汀对急性冠状动脉综合征(ACS)患者炎性因子C反应蛋白(CRP)及血脂的影响。方法将2013年5月至2014年1月河北北方学院附属第一医院心内科住院治疗的110例ACS患者依据用药剂量的不同分为三组:对照组38例、低剂量组36例和高剂量组36例,对照组给予抗血小板聚集、硝酸酯类、β受体阻滞剂、低分子肝素常规治疗,低剂量组在常规治疗基础上给予瑞舒伐他汀10 mg,每晚1次,高剂量组在常规治疗基础上给予瑞舒伐他汀20 mg,每晚1次。比较三组患者用药前后血脂水平及C反应蛋白的变化情况。结果三组患者治疗后7 d、30 d CRP均有所下降。对照组治疗前CRP为(9.08±0.30)mg/L,治疗后7 d为(7.43±0.41)mg/L、30 d为(6.03±0.34)mg/L;低剂量组治疗前为(9.12±0.28)mg/L,治疗后7 d为(6.04±0.44)mg/L、30 d为(4.42±0.38)mg/L;高剂量组治疗前为(8.98±0.34)mg/L,治疗后7 d为(5.88±0.22)mg/L、30 d为(3.02±0.33)mg/L,且低剂量组和高剂量组下降幅度均优于对照组(P<0.05)。低剂量组和高剂量组患者治疗后7 d、30 d三酰甘油、总胆固醇、低密度脂蛋白胆固醇均下降,高密度脂蛋白胆固醇水平均升高,且高剂量组降脂效果优于低剂量组,差异均有统计学意义(P<0.05)。结论瑞舒伐他汀治疗ACS可以降低血脂水平,减轻炎性反应及稳定斑块。

Effect of Rosuvastatin Calcium on C-reactive Protein and Lipids in Patients with Acute Coronary Syndrome

Objective To investigate the effect of rosuvastatin calcium on inflammatory factors C-reactive protein（CRP） and lipids in patients with acute coronary syndrome（ACS）.Methods Totally 110 patients with ACS from the Fist Affiliated Hospital of Hebei North University during May 2013 and Jan.2014were included in the study.The patients were randomly divided into three groups：the control group（n =38）,the low-dose group（n =36） and the high-dose group（n =36）.All patients in three groups were given antibloodplatelet,nitrates,β-blocker.Based on these medications,the low-dose group was given rosuvastatin 10 mg,once a night ; the high-dose group was given rosuvastatin 20 mg,once a night.The levels of C-reactive protein and lipids were measured before and after treatment in all of the groups.Results CRP of the three groups after 7 d,30 d declined.CRP of the control group before treatment was （9.08 ± 0.30） mg/L,7 dafter treatment was （7.43 ± 0.41） mg/L,30 d after treatment was （6.03 ± 0.34） mg/L ; CRP of low-dose group before treatment was （9.12 ± 0.28） mg/L,7 d after treatment was （6.04 ± 0.44） mg/L,30 d after treatment was （4.42 ± 0.38） mg/L; CRP of high-dose group before treatment was （8.98 ± 0.34） mg/L,7 dafter treatment was （5.88 ± 0.22） mg/L,30 d after treatment was （3.02 ± 0.33） mg/L,and the decline of low-dose group and high-dose group were better than the control group（P 〈 0.05）.The triglyceride,total cholesterol,LDL cholesterol of low-dose and high-dose group after 7 d,30 d treatment decreased,while the HDL cholesterol levels all increased,and fat-lowering effect of the high-dose group was better than low-dose group,with statistically significant difference（P 〈 0.05）.Conclusion Rosuvastatin calcium in treatment of ACS can reduce cholesterol level,lessen the inflammatory response,and stabilize the atherosclerosis plaque.